NICE hopes to play starring role in UK value-based pricing system
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, is confident that it has an important role to play in the UK's new value-based pricing (VBP) system, which is scheduled to start by 1 January 2014.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.